X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate the ability of RLS-0071, a novel 15 amino acid peptide dual-targeting anti-inflammatory inhibitor of complement and neutrophil effectors, to mitigate the gastrointestinal effects of ARS (GI-ARS) in a preclinical mouse model.
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: ReAlta Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2024
Details:
The funding aims to support the company's ongoing development of GM-3009 (ibogaine), a Kappa opioid receptor agonist. It is evaluated in the Preclinical trials for the treatment of Opioid-Related Disorders.
Lead Product(s): Ibogaine
Therapeutic Area: Psychiatry/Psychology Product Name: GM-3009
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Gilgamesh Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 14, 2024
Details:
The net proceeds from the funding will be used for the development of SA53, a novel MDM2 inhibitor, for the treatment of p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue.
Lead Product(s): SA53
Therapeutic Area: Oncology Product Name: SA53
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Lamassu Pharma
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 12, 2024
Details:
The funding helps BioCorRx to focus on the clinical development of BICX104 (naltrexone) a biodegradable, long-acting subcutaneous pellet in combination with Bupropion. It is currently evaluated in preclinical studies for methamphetamine use disorder.
Lead Product(s): Naltrexone,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: BioCorRx
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 28, 2024
Details:
The financing aims to support Blacksmith to focus on the development of FG-2101, its novel non-hydroxamate LpxC inhibitor, using both intravenous and oral administration for the treatment of urinary tract infections caused by multidrug-resistant Gram-negative bacteria.
Lead Product(s): FG-2101
Therapeutic Area: Infections and Infectious Diseases Product Name: FG-2101
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Blacksmith Medicines
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Funding February 21, 2024
Details:
The net proceeds will fund longer toxicology studies and drug manufacturing of SBP-9330, a small molecule that targets a receptor called metabotropic glutamate receptor 2 (mGlu2) to support planned Phase 2 studies for nicotine cessation.
Lead Product(s): SBP-9330
Therapeutic Area: Psychiatry/Psychology Product Name: SBP-9330
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Camino Pharma
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 06, 2024
Details:
The collaboration aims to support Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2.
Lead Product(s): Exosome-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: StealthX
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Capricor Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 24, 2024
Details:
Under the agreement, Syena will expand its pipeline of engineered T-Cell Receptor-Natural Killer (TCR-NK) cell therapies targeting NY-ESO-1, SY-101, by gaining NIH's intellectual property related to a library of TCRs directed against multiple cancer neoantigens.
Lead Product(s): SY-101
Therapeutic Area: Oncology Product Name: SY-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2023
Details:
The funding will support the clinical development of Daré’s novel, investigational intravaginal ring (IVR), DARE-PTB1 (progesterone), being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options.
Lead Product(s): Bio-identical Progesterone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: DARE-PTB1
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Daré Bioscience
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Details:
The grant will support further development of novel neuroplastogen and ibogaine analog, DLX-007, a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.
Lead Product(s): DLX-007
Therapeutic Area: Psychiatry/Psychology Product Name: DLX-007
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Delix Therapeutics
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
